Nasdaq

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) ...

Ewha Womans University Seoul Hospital Administers 'Elahere' Ovarian Cancer ADC Therapy for First Time in Asia

Ewha Womans University Seoul Hospital announced on July 22 that the team of Professors Hyesung Moon, Woong Joo, and Hagyun ...
Cancer Therapy Advisor

ASCO Releases Guideline for Treatment of Recurrent Ovarian Cancer

The preferred management of patients with recurrent platinum-sensitive ovarian cancer (PSOC) is platinum-based doublet therapy with selective ...

Ovarian cancer breakthrough: New targeted drug extends survival, improves quality of life

A breakthrough targeted therapy, mirvetuximab soravtansine, is offering new hope to women with hard-to-treat ovarian cancer. Studies show it extends survival, slows disease progression, shrinks ...
Nasdaq

Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level; Confirmed objective response rate (cORR) of 78 ...
Cure Today

Rina-S Generates Antitumor Activity in Heavily Pretreated Ovarian Cancer

Treatment with Rina-S showed antitumor activity in heavily pretreated patients with advanced ovarian cancer, according to the phase 2 RAINFOL-01 study. Treatment with rinatabart sesutecan (Rina-S), a ...
The American Journal of Managed Care

Dr Toon Van Gorp: Mirvetuximab Soravtansine Should Be Global Standard for FRα+ Ovarian Cancer

Toon Van Gorp, MD, PhD, a MIRASOL trial investigator, emphasizes that the final analysis reinforces the efficacy of mirvetuximab soravtansine-gynx (Elahere; AbbVie) in patients with folate receptor ...
The American Journal of Managed Care

Final PICCOLO Data Highlight Efficacy of Mirvetuximab Soravtansine in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

Mirvetuximab soravtansine-gynx showed notable efficacy in folate receptor alpha-positive, third-line or later recurrent platinum-sensitive ovarian cancer, with a median OS of 27.17 months. Patients ...
Healio

VIDEO: Response seen with Rina-S in ovarian cancer despite FR-alpha expression levels

Please provide your email address to receive an email when new articles are posted on . In this video, Ursula A. Matulonis, MD, discusses new data on rinatabart sesutecan, or Rina-S, for patients with ...
Business Wire

ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the US Food and ...